Multiparameter urine analysis for quantitative bladder cancer surveillance of orthotopic xenografted mice.

The human-derived orthotopic xenograft mouse model is an effective platform for performing in vivo bladder cancer studies to examine tumor development, metastasis, and therapeutic effects of drugs. To date, the surveillance of tumor progression in real time for orthotopic bladder xenografts is highly dependent on semi-quantitative in vivo imaging technologies such as bioluminescence.

While these imaging technologies can estimate tumor progression, they are burdened with requirements such as anesthetics, specialized equipment, and genetic modification of the injected cell line. Thus, a convenient and non-invasive technology to quantitatively monitor the growth of bladder cancer in orthotopic xenografts is highly desired. In this work, using a microfluidic chemiluminescent ELISA platform, we have successfully developed a rapid, multiparameter urine-based and non-invasive biomolecular prognostic technology for orthotopic bladder cancer xenografts. This method consists of two steps. First, the concentrations of a panel of four urinary biomarkers are quantified from the urine of mice bearing orthotopic bladder xenografts. Second, machine learning and principal component analysis (PCA) algorithms are applied to analyze the urinary biomarkers, and subsequently, a score is assigned to indicate the tumor growth. With this methodology, we have quantitatively monitored the orthotopic growth of human bladder cancer that was inoculated with low, medium, and high cancer cell numbers. We also employed this method and performed a proof of principle experiment to examine the in vivo therapeutic efficacy of the EGFR inhibitor, dacomitinib.

Lab on a chip. 2020 Jan 10 [Epub ahead of print]

Xiaotian Tan, Luke J Broses, Menglian Zhou, Kathleen C Day, Wenyi Liu, Ziqi Li, Alon Z Weizer, Katherine A Munson, Maung Kyaw Khaing Oo, Mark L Day, Xudong Fan

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. ., Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA. and Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA., Optofluidic Bioassay, LLC, 674 S. Wagner Rd., Ann Arbor, MI 48103, USA.

Go Beyond the Abstract and Read a Commentary by the Authors 

email news signup